Harry BarnettExecutive Vice President, Alira Health Clinical

    Harry Barnett

    Executive Vice President, Alira Health Clinical

    Harry Barnett, JD, is the Executive Vice President of Alira Health Clinical. Harry joined Alira Health in February 2018 when his CRO, known as Clinical Assistance Programs (CAP), was acquired by the firm. He is now responsible for commercial strategy and clinical oversight.

    Harry’s life science career includes founding and operating several highly-respected CROs, developing and commercializing a wide array of pharmaceutical technologies at various stages, and innovating clinical trial processes to enhance outcomes. In addition to his founding and operating CAP, a US-based, specialty CRO, Harry’s career highlights include founding and executive leadership roles at multiple companies, including Biomodels, a prominent preclinical CRO based in Eastern Massachusetts; Receptor, Inc., whose lead technology was licensed by a Johnson & Johnson Merck joint venture resulting in the successful commercialization of the OTC heartburn product, Pepcid Complete; and Lubris BioPharma, a clinical-stage biotechnology company whose lead product was acquired and is currently being developed by Novartis AG.

    Prior to his professional career, Harry received his bachelor’s degree from Tufts University and his Juris Doctor degree from Boston University School of Law.

    Click here to watch Harry’s recent webinar on The Future of Clinical Trial Monitoring: Will remote or in-person monitoring rule post-COVID-19?